Abstract
In this article we analyse the market for drugs in health care markets where third payers (an insurance company or a government agency) bear the cost and we suggest a common and transparent methodology to set the price for new drugs as well as active principles for which an alternative already exists. We argue that in this context a bargaining approach is the most suitable instrument to describe the price setting procedure and we show how this approach can be implemented. We argue that many of the systems that are used by western countries are in fact simplified application of our model, the main difference usually being that the actual price setting procedure is not as transparent as the one we propose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
